NCIC Clinical Trials Group

🇨🇦Canada

Country: 🇨🇦Canada

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma

Phase 1

Withdrawn

Conditions: Neuroblastoma

Interventions: Drug: Imetelstat

First Posted Date: 2013-08-05

Last Posted Date: 2020-09-21

Lead Sponsor: NCIC Clinical Trials Group

Registration Number: NCT01916187

Locations: 🇨🇦
CHU Sainte-Justine, Montreal, Quebec, Canada

BBI608 and Best Supportive Care vs Placebo and Best Supportive Care in Pretreated Advanced Colorectal Carcinoma

Phase 3

Completed

Conditions: Colorectal Carcinoma

Interventions: Drug: BBI608
Drug: Placebo
Other: Best Supportive Care

First Posted Date: 2013-04-12

Last Posted Date: 2023-08-28

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 282

Registration Number: NCT01830621

Locations: 🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada
🇯🇵
Chiba Cancer Center, Chiba, Japan
🇦🇺
St John of God - Subiaco, Subiaco, Western Australia, Australia

and more 60 locations

A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Mantle Cell Lymphoma

Interventions: Drug: AT7519M

First Posted Date: 2012-07-27

Last Posted Date: 2023-08-04

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 12

Registration Number: NCT01652144

Locations: 🇨🇦
McGill University - Dept. Oncology, Montreal, Quebec, Canada
🇨🇦
Allan Blair Cancer Centre, Regina, Saskatchewan, Canada
🇨🇦
CancerCare Manitoba, Winnipeg, Manitoba, Canada

and more 3 locations

A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: AT7519M

First Posted Date: 2012-06-25

Last Posted Date: 2023-08-04

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 7

Registration Number: NCT01627054

Locations: 🇨🇦
CancerCare Manitoba, Winnipeg, Manitoba, Canada
🇨🇦
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦
Univ. Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada

A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma

Phase 2

Completed

Conditions: Malignant Pleural Mesothelioma

Interventions: Drug: PF-03446962

First Posted Date: 2011-12-06

Last Posted Date: 2023-08-04

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 17

Registration Number: NCT01486368

Locations: 🇨🇦
CancerCare Manitoba, Winnipeg, Manitoba, Canada
🇨🇦
BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada

and more 4 locations

A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: PX-866

First Posted Date: 2011-04-07

Last Posted Date: 2023-08-22

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 68

Registration Number: NCT01331083

Locations: 🇨🇦
London Regional Cancer Program, London, Ontario, Canada
🇨🇦
Cancer Centre of Southeastern Ontario at Kingston, Kingston, Ontario, Canada
🇨🇦
BCCA - Cancer Centre for the Southern Interior, Kelowna, British Columbia, Canada

and more 7 locations

A Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression

Phase 2

Completed

Conditions: Glioblastoma

Interventions: Drug: PX-866

First Posted Date: 2010-12-14

Last Posted Date: 2023-08-22

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 34

Registration Number: NCT01259869

Locations: 🇨🇦
Allan Blair Cancer Centre, Regina, Saskatchewan, Canada
🇨🇦
London Regional Cancer Program, London, Ontario, Canada
🇨🇦
CancerCare Manitoba, Winnipeg, Manitoba, Canada

and more 4 locations

Dexamethasone vs Placebo in the Prophylaxis of Radiation-Induced Pain Flare Following Palliative Radiotherapy for Bone Metastases

Phase 3

Completed

Conditions: Bone Metastases

Interventions: Drug: Placebo
Drug: Dexamethasone

First Posted Date: 2010-11-25

Last Posted Date: 2023-08-28

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 298

Registration Number: NCT01248585

Locations: 🇨🇦
CancerCare Manitoba, Winnipeg, Manitoba, Canada
🇨🇦
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦
Cancer Centre of Southeastern Ontario at Kingston, Kingston, Ontario, Canada

and more 19 locations

A Phase I Study of SB939 in Pediatric Patients With Refractory Solid Tumours and Leukemia

Phase 1

Completed

Conditions: Leukemia
Solid Tumours

Interventions: Drug: SB939

First Posted Date: 2010-08-18

Last Posted Date: 2023-08-04

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 12

Registration Number: NCT01184274

Locations: 🇨🇦
Hospital for Sick Children, Toronto, Ontario, Canada
🇨🇦
Children's and Women's Health Centre of BC Branch, Vancouver, British Columbia, Canada
🇨🇦
Alberta Children's Hospital, Calgary, Alberta, Canada

and more 5 locations

Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma

Phase 2

Completed

Conditions: Melanoma

Interventions: Drug: rIL-21
Drug: Dacarbazine

First Posted Date: 2010-06-29

Last Posted Date: 2023-08-22

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 64

Registration Number: NCT01152788

Locations: 🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada
🇨🇦
Atlantic Health Sciences Corporation, Saint John, New Brunswick, Canada
🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States

and more 16 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy